[(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial

Amit Agrawal, Francisco J Civantos, Kevin T Brumund, Douglas B Chepeha, Nathan C Hall, William R Carroll, Russell B Smith, Robert P Zitsch, Walter T Lee, Yelizaveta Shnayder, David M Cognetti, Karen T Pitman, Dennis W King, Lori A Christman, Stephen Y Lai, Amit Agrawal, Francisco J Civantos, Kevin T Brumund, Douglas B Chepeha, Nathan C Hall, William R Carroll, Russell B Smith, Robert P Zitsch, Walter T Lee, Yelizaveta Shnayder, David M Cognetti, Karen T Pitman, Dennis W King, Lori A Christman, Stephen Y Lai

Abstract

Background: [(99m)Tc]Tilmanocept, a novel CD206 receptor-targeted radiopharmaceutical, was evaluated in an open-label, phase III trial to determine the false negative rate (FNR) of sentinel lymph node biopsy (SLNB) relative to the pathologic nodal status in patients with intraoral or cutaneous head and neck squamous cell carcinoma (HNSCC) undergoing tumor resection, SLNB, and planned elective neck dissection (END). Negative predictive value (NPV), overall accuracy of SLNB, and the impact of radiopharmaceutical injection timing relative to surgery were assessed.

Methods and findings: This multicenter, non-randomized, single-arm trial (ClinicalTrials.gov identifier NCT00911326) enrolled 101 patients with T1-T4, N0, and M0 HNSCC. Patients received 50 µg [(99m)Tc]tilmanocept radiolabeled with either 0.5 mCi (same day) or 2.0 mCi (next day), followed by lymphoscintigraphy, SLNB, and END. All excised tissues were evaluated for tissue type and tumor presence. [(99m)Tc]Tilmanocept identified one or more SLNs in 81 of 83 patients (97.6 %). Of 39 patients identified with any tumor-positive nodes (SLN or non-SLN), one patient had a single tumor-positive non-SLN in whom all SLNs were tumor-negative, yielding an FNR of 2.56 %; NPV was 97.8 % and overall accuracy was 98.8 %. No significant differences were observed between same-day and next-day procedures.

Conclusions: Use of receptor-targeted [(99m)Tc]tilmanocept for lymphatic mapping allows for a high rate of SLN identification in patients with intraoral and cutaneous HNSCC. SLNB employing [(99m)Tc]tilmanocept accurately predicts the pathologic nodal status of intraoral HNSCC patients with low FNR, high NPV, and high overall accuracy. The use of [(99m)Tc]tilmanocept for SLNB in select patients may be appropriate and may obviate the need to perform more extensive procedures such as END.

Figures

Fig. 1
Fig. 1
SPECT/CT three-dimensional fused reconstruction cross-sectional images of a typical patient with floor-of-mouth tumor (duration of SPECT/CT acquisition was 3–21 min post-injection of [99mTc]tilmanocept. The cube in the lower right corner indicates the perspective of the image. SPECT single-photon emission computed tomography, CT computed tomography, R right, L left, H head, F feet, A anterior, P posterior

References

    1. Alvi A, Johnson JT. Extracapsular spread in the clinically negative neck (N0): implications and outcome. Otolaryngol Head Neck Surg. 1996;114:65–70. doi: 10.1016/S0194-5998(96)70285-1.
    1. Mamelle G, Pampurik J, Luboinski B, et al. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg. 1994;168:494–498. doi: 10.1016/S0002-9610(05)80109-6.
    1. Rassekh CH, Johnson JT, Myers EN. Accuracy of intraoperative staging of the N0 neck in squamous cell carcinoma. Laryngoscope. 1995;105:1334–1336. doi: 10.1288/00005537-199512000-00013.
    1. de Bondt RB, Nelemans PJ, Hofman PA, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol. 2007;64:266–272. doi: 10.1016/j.ejrad.2007.02.037.
    1. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100:712–720. doi: 10.1093/jnci/djn125.
    1. Yuen AP, Wei WI, Wong YM, et al. Elective neck dissection versus observation in the treatment of early oral tongue carcinoma. Head Neck. 1997;19:583–588. doi: 10.1002/(SICI)1097-0347(199710)19:7<583::AID-HED4>;2-3.
    1. Chepeha DB, Taylor RJ, Chepeha JC, et al. Functional assessment using Constant’s Shoulder Scale after modified radical and selective neck dissection. Head Neck. 2002;24:432–436. doi: 10.1002/hed.10067.
    1. Rogers SN, Ferlito A, Pellitteri PK, et al. Quality of life following neck dissections. Acta Otolaryngol. 2004;124:231–236. doi: 10.1080/00016480310015317.
    1. Schiefke F, Akdemir M, Weber A, et al. Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection. Head Neck. 2009;31:503–512. doi: 10.1002/hed.21001.
    1. Schmitz S, Machiels JP, Weynand B, et al. Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2009;266:437–443. doi: 10.1007/s00405-008-0767-9.
    1. Chone CT, Magalhes RS, Etchehebere E, et al. Predictive value of sentinel node biopsy in head and neck cancer. Acta Otolaryngol. 2008;128:920–924. doi: 10.1080/00016480701760114.
    1. Bilde A, von Buchwald C, Therkildsen MH, et al. Need for intensive histopathologic analysis to determine lymph node metastases when using sentinel node biopsy in oral cancer. Laryngoscope. 2008;118:408–414. doi: 10.1097/MLG.0b013e31815d8e15.
    1. Civantos FJ, Moffat FL, Goodwin WJ. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: contrasts between oral cavity and cutaneous malignancy. Laryngoscope. 2006;112:1–15. doi: 10.1097/01.mlg.0000200750.74249.79.
    1. Civantos FJ, Zitsch RP, Schuller DE, et al. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1–T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010;28:1395–1400. doi: 10.1200/JCO.2008.20.8777.
    1. Shoaib T, Soutar DS, MacDonald DG, et al. The accuracy of head and neck carcinoma sentinel lymph node biopsy in the clinically N0 neck. Cancer. 2001;91:2077–2083. doi: 10.1002/1097-0142(20010601)91:11<2077::AID-CNCR1235>;2-E.
    1. Zitsch RP, 3rd, Todd DW, Renner GJ, et al. Intraoperative radiolymphoscintigraphy for detection of occult nodal metastasis in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2000;122:662–666. doi: 10.1067/mhn.2000.104017.
    1. Civantos FJ, Gomez C, Duque C, et al. Sentinel node biopsy in oral cavity cancer: correlation with PET scan and immunohistochemistry. Head Neck. 2003;25:1–9. doi: 10.1002/hed.10213.
    1. Alkureishi LW, Ross GL, Shoaib T, et al. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial. Ann Surg Oncol. 2010;17:2459–2464. doi: 10.1245/s10434-010-1111-3.
    1. Vera DR, Wallace AM, Hoh CK, et al. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextra. J Nucl Med. 2001;42:951–959.
    1. Ross GL, Soutar DS, MacDonald GD, et al. Sentinel node biopsy in head and neck cancer: preliminary results of a multicenter trial. Ann Surg Oncol. 2004;11:690–696. doi: 10.1245/ASO.2004.09.001.
    1. Civantos FJ, Agrawal A, Lai SY. Comparison of false negative rates and overall accuracy of sentinel lymph node biopsy in phase 3 99mTc-tilmanocept vs ACOSOG Z-0360 99mTc-sulfur colloid in head/neck squamous cell cancer. In: Society of nuclear medicine and molecular imaging annual meeting, 11 Jun 2013, Vancouver.
    1. Wallace AM, Hoh CK, Limmera KK, et al. Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a “2-day” protocol. Nucl Med Biol. 2009;36:687–692. doi: 10.1016/j.nucmedbio.2009.04.007.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel